Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 765-777

  Moschen, Alexander R ^a   Molnar, Clemens ^a   Wolf, Anna Maria ^a   Weiss, Helmut ^a   Graziadei, Ivo ^a   Kaser, Susanne ^a   Ebenbichler, Christoph F ^a   Stadlmann, Sylvia ^b   Moser, Patrizia L ^c   Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Kantonsspital Baden   (Switzerland)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Adipocytokine; Bariatric surgery; NAFLD; NASH; Weight loss

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BARIATRIC SURGERY; BLOOD LEVEL; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HISTOLOGY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WEIGHT REDUCTION;

ADIPOKINES; ADIPONECTIN; ADULT; BARIATRIC SURGERY; BASE SEQUENCE; CYTOKINES; DNA PRIMERS; FATTY LIVER; FEMALE; GASTROPLASTY; GENE EXPRESSION; HUMANS; LEPTIN; LIVER; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY, MORBID; PROSPECTIVE STUDIES; RESISTIN; RNA, MESSENGER; WEIGHT LOSS;

EID: 70249115442     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.06.016     Document Type: Article

References (68)

1. Tilg H., and Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 148-155
2. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
3. Marchesini G., and Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35 (2002) 497-499
4. Tilg H., and Hotamisligil G.S. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131 (2006) 934-945
5. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., and Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54 (2005) 603-608
6. Dixon J.B., Bhathal P.S., Hughes N.R., and O'Brien P.E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
7. Kral J.G., Thung S.N., Biron S., Hould F.S., Lebel S., Marceau S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135 (2004) 48-58
8. Silverman E.M., Sapala J.A., and Appelman H.D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 104 (1995) 23-31
9. Luyckx F.H., Desaive C., Thiry A., Dewe W., Scheen A.J., Gielen J.E., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 (1998) 222-226
10. Chapman A.E., Kiroff G., Game P., Foster B., O'Brien P., Ham J., et al. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review. Surgery 135 (2004) 326-351
11. Tilg H., and Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 (2006) 772-783
12. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
13. Combs T.P., Berg A.H., Obici S., Scherer P.E., and Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108 (2001) 1875-1881
14. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
15. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (2002) 731-737
16. Wolf A.M., Wolf D., Rumpold H., Enrich B., and Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323 (2004) 630-635
17. Heymsfield S.B., Greenberg A.S., Fujioka K., Dixon R.M., Kushner R., Hunt T., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282 (1999) 1568-1575
18. Matarese G., Moschos S., and Mantzoros C.S. Leptin in immunology. J Immunol 174 (2005) 3137-3142
19. Tilg H., and Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 114 (2008) 275-288
20. Kusminski C.M., McTernan P.G., and Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci (Lond) 109 (2005) 243-256
21. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
22. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with pro-inflammatory and immunomodulating properties. J Immunol 178 (2007) 1748-1758
23. Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113 (2004) 1318-1327
24. Ye S.Q., Simon B.A., Maloney J.P., Zambelli-Weiner A., Gao L., Grant A., et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 171 (2005) 361-370
25. Otero M., Lago R., Gomez R., Lago F., Dieguez C., Gomez-Reino J.J., et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1198-1201
26. Weiss H.G., Nehoda H., Labeck B., Peer-Kuehberger R., Oberwalder M., Aigner F., et al. Adjustable gastric and esophagogastric banding: a randomized clinical trial. Obes Surg 12 (2002) 573-578
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
28. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 135 (2008) 100-110
29. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
30. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., and Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
31. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005) 117-121
32. Bertolani C., Sancho-Bru P., Failli P., Bataller R., Aleffi S., DeFranco R., et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 169 (2006) 2042-2053
33. Supplement 1. American Diabetes Association: clinical practice recommendations 2000. Diabetes Care 2000;23(Suppl 1):S1-116.
34. Jonsson J.R., Moschen A.R., Hickman I.J., Richardson M.M., Kaser S., Clouston A.D., et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 43 (2005) 929-936
35. Tilg H., and Moschen A.R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19 (2008) 371-379
36. Chitturi S., Farrell G., Frost L., Kriketos A., Lin R., Fung C., et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 36 (2002) 403-409
37. Nakao K., Nakata K., Ohtsubo N., Maeda M., Moriuchi T., Ichikawa T., et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 97 (2002) 1796-1801
38. Zhou J., Lei W., Shen L., Luo H.S., and Shen Z.X. Primary study of leptin and human hepatocellular carcinoma in vitro. World J Gastroenterol 14 (2008) 2900-2904
39. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
40. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., and George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
41. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 (2003) 1796-1807
42. Masaki T., Chiba S., Tatsukawa H., Yasuda T., Noguchi H., Seike M., et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40 (2004) 177-184
43. Sennello J.A., Fayad R., Morris A.M., Eckel R.H., Asilmaz E., Montez J., et al. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 146 (2005) 2157-2164
44. Ballantyne G.H., Gumbs A., and Modlin I.M. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 15 (2005) 692-699
45. Baratta R., Amato S., Degano C., Farina M.G., Patane G., Vigneri R., et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89 (2004) 2665-2671
46. Pelleymounter M.A., Cullen M.J., Baker M.B., Hecht R., Winters D., Boone T., et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269 (1995) 540-543
47. Oral E.A., Simha V., Ruiz E., Andewelt A., Premkumar A., Snell P., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346 (2002) 570-578
48. Giannini E., Botta F., Cataldi A., Tenconi G.L., Ceppa P., Barreca T., et al. Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C. Hepatogastroenterology 46 (1999) 2422-2425
49. Manco M., Marcellini M., Giannone G., and Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127 (2007) 954-960
50. Wong V.W., Hui A.Y., Tsang S.W., Chan J.L., Tse A.M., Chan K.F., et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4 (2006) 1154-1161
51. Lord G.M., Matarese G., Howard J.K., Baker R.J., Bloom S.R., and Lechler R.I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394 (1998) 897-901
52. Matarese G., Di Giacomo A., Sanna V., Lord G.M., Howard J.K., Di Tuoro A., et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 166 (2001) 5909-5916
53. Ikejima K., Takei Y., Honda H., Hirose M., Yoshikawa M., Zhang Y.J., et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122 (2002) 1399-1410
54. Leclercq I.A., Farrell G.C., Schriemer R., and Robertson G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37 (2002) 206-213
55. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
56. Pagano C., Soardo G., Pilon C., Milocco C., Basan L., Milan G., et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91 (2006) 1081-1086
57. Zou C.C., Liang L., Hong F., Fu J.F., and Zhao Z.Y. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 52 (2005) 519-524
58. Younossi Z.M., Jarrar M., Nugent C., Randhawa M., Afendy M., Stepanova M., et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18 (2008) 1430-1437
59. Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009; pii: 37273. doi:10.1172/JCI37273. [Epub ahead of print].
60. Harrison S.A., Fecht W., Brunt E.M., and Neuschwander-Tetri B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49 (2009) 80-86
61. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108 (2003) 736-740
62. Silswal N., Singh A.K., Aruna B., Mukhopadhyay S., Ghosh S., and Ehtesham N.Z. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 334 (2005) 1092-1101
63. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14 (1994) 1431-1437
64. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32 (2002) 3225-3234
65. Wang T., Zhang X., Bheda P., Revollo J.R., Imai S., and Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 13 (2006) 661-662
66. Kitani T., Okuno S., and Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 544 (2003) 74-78
67. Koczan D., Guthke R., Thiesen H.J., Ibrahim S.M., Kundt G., Krentz H., et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 15 (2005) 251-257
68. Manco M., Fernandez-Real J.M., Equitani F., Vendrell J., Valera Mora M.E., Nanni G., et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 92 (2007) 483-490